PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES
PERRY DRUG HAS MORE AUTO PARTS UNITS THAN DRUG STORES following Perry's acquisition of 46 Corvair discount auto parts stores. The acquisition of the Columbus, Ohio-based auto chain with annual sales of approximately $22 mil. will raise the number of auto stores operated by Perry to 150, compared with 143 drug stores, according to an Oct. 10 release announcing a definitive agreement between the two firms. The acquisition is the fifth by Perry in as many months, and the third purchase of an auto parts chain since June. Automotive sales are expected to account for as much as 22% of total sales for Perry in fiscal 1984, which ends Oct. 31, a company spokesman told "The Pink Sheet." Last year, net automotive sales were $40.1 mil., representing 14% of Perry's total net sales of $200.2 mil. Rx volume remains a key segment in Perry's sales mix, however. In 1983, Rx sales increased 35% to $56.4 mil., representing approximately 20% of total sales. Rx and automotive sales combined are expected to account for between 40% to 43% of total sales in fiscal 1984. According to a company spokesman, Perry's goal is for combined automotive and Rx sales to reach 50% of the chain's total sales within the next few years.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.
Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.
With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.